1. Volume 64, Issue 6, Pages 2188-2195 (December 2003)
Amlodipine reverses the elevation in [Ca2+]i and the impairment of phagocytosis in PMNLs of NIDDM patients 
E.W.A. Krol, Rubina Agueel, Sultana Banue, Miroslaw Smogorzewski, Dinesh Kumar, Shaul G. Massry 
Kidney International 
Volume 64, Issue 6, Pages (December 2003)
DOI: /j x
Copyright © 2003 International Society of Nephrology Terms and Conditions

2. Figure 1
Cytosolic calcium of polymorphonuclear leukocytes (PMNLs) from normal subjects, diabetic patients without and with treatment with amlodipine. Each data point represents one patient and the brackets denote mean ± 1 SE. NIDDM is noninsulin-dependent diabetes mellitus.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

3. Figure 2
Phagocytosis by polymorphonuclear leukocytes (PMNLs) expressed by the injection rate of oil particles from normal subjects and from diabetic patients with and without treatment with amlodipine. Each data point represents one patient and the brackets denote mean ± 1 SE. NIDDM is noninsulin-dependent diabetes mellitus.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

4. Figure 3
The ratio of the mRNA of FC γ RIII to β-actin in polymorphonuclear leukocytes (PMNLs) from normal subjects (□) and from diabetic patients with (▪) and without () treatment with amlodipine. The columns represent the mean values and the brackets denote mean ± 1 SE. **P < 0.01 vs. the other two groups.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

5. Figure 4
Changes in cytosolic calcium of polymorphonuclear leukocytes (PMNLs) (A) and phagocytosis (B) observed in the 10 diabetic patients before, during, and after cessation of nifedipine therapy. Each line represents one patient. These patients were hyperglycemic throughout the entire period of the study and there were no differences in the blood levels of fasting glucose and hemoglobin A1c at the various points of the study (see Table 2).
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions